8-K: GlucoTrack Faces Nasdaq Delisting Threat After Failing to Meet Minimum Bid Price and Stockholders' Equity Requirements

GlucoTrack, Inc. is facing potential delisting from the Nasdaq Stock Market after failing to meet minimum bid price and stockholders' equity requirements, and has requested a hearing to appeal the decision.

Summary

• GlucoTrack, Inc. received a notification from Nasdaq on May 21, 2024, stating that the company has not regained compliance with the minimum bid price requirement of $1.00 per share.
• The company also failed to meet the minimum stockholders' equity requirement of $2,500,000 for continued listing.
• Due to the ongoing review for the minimum bid price deficiency, GlucoTrack is not eligible to submit a plan to regain compliance for the equity requirement.
• Unless the company appeals by May 28, 2024, trading of its common stock will be suspended on May 30, 2024.
• GlucoTrack has requested a hearing with a Nasdaq Hearings Panel, which will temporarily halt any suspension or delisting action.
• The company previously implemented a 1-for-5 reverse stock split on May 17, 2024, in an attempt to regain compliance with the minimum bid price requirement.
• At the hearing, GlucoTrack intends to request a 180-day extension to raise additional capital to meet the minimum stockholders' equity requirement.
• There is no guarantee that the company will be able to satisfy Nasdaq's listing requirements or maintain its listing.

Sentiment

Score: 3

Explanation: The document indicates significant challenges for the company, including potential delisting and the need for a capital raise, which is generally viewed negatively by investors.

Positives

• GlucoTrack has requested a hearing with the Nasdaq Hearings Panel, which will temporarily prevent the suspension of trading.
• The company is seeking a 180-day extension to raise capital and meet the minimum stockholders' equity requirement.

Negatives

• GlucoTrack has failed to meet both the minimum bid price and minimum stockholders' equity requirements for continued listing on Nasdaq.
• The company is facing potential delisting from Nasdaq if the appeal is unsuccessful.
• There is no assurance that the company will be able to regain compliance with Nasdaq's listing requirements.

Risks

• There is a risk that the Nasdaq Hearings Panel will not grant the company's request for continued listing.
• The company may not be able to raise sufficient capital to meet the minimum stockholders' equity requirement.
• Failure to regain compliance could result in the delisting of GlucoTrack's common stock from Nasdaq.
• The company's stock price could be negatively impacted by the delisting threat.

Future Outlook

The company is seeking a hearing to appeal the delisting and intends to request a 180-day extension to raise capital. However, there is no guarantee of success.

Management Comments

• The company intends to request an extension of 180 days to raise additional capital to meet the listing requirement.
• The company is working to regain compliance with Nasdaq listing requirements.

Industry Context

This situation is not uncommon for small-cap companies, particularly in the biotech sector, that may face challenges in maintaining share price and equity levels. Many companies in similar situations have had to undergo reverse stock splits and capital raises to maintain their listing.

Comparison to Industry Standards

• Many small-cap biotech companies face similar challenges in maintaining Nasdaq listing compliance.
• Reverse stock splits are a common strategy used by companies to increase their share price and meet minimum bid requirements.
• Companies like Aeterna Zentaris and Oramed Pharmaceuticals have also faced delisting threats and have had to implement similar strategies to regain compliance.
• The need to raise additional capital to meet minimum equity requirements is also a common challenge for companies in this sector.

Stakeholder Impact

• Shareholders face the risk of delisting and potential loss of investment value.
• Employees may experience uncertainty due to the company's financial challenges.
• Customers and suppliers may be concerned about the company's long-term viability.

Next Steps

• GlucoTrack will attend a hearing with the Nasdaq Hearings Panel.
• The company will seek a 180-day extension to raise capital.
• The company will need to regain compliance with Nasdaq listing requirements.

Key Dates

Keywords

delisting, Nasdaq, minimum bid price, stockholders' equity, reverse stock split, compliance, hearing, capital raise, GCTK